{"id":"vaccination-with-gardasil","safety":{"commonSideEffects":[{"rate":"48–83%","effect":"Injection site pain, swelling, or erythema"},{"rate":"10–15%","effect":"Headache"},{"rate":"5–10%","effect":"Myalgia"},{"rate":"1–3%","effect":"Fever"},{"rate":"<1%","effect":"Syncope (fainting)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains virus-like particles (VLPs) derived from the major capsid protein of four HPV types. Upon administration, these VLPs trigger a humoral immune response that generates neutralizing antibodies, which prevent infection by these HPV strains. This prophylactic approach prevents HPV-related cancers and diseases including cervical cancer, anal cancer, and genital warts.","oneSentence":"Gardasil is a recombinant quadrivalent human papillomavirus (HPV) vaccine that stimulates the immune system to produce antibodies against HPV types 6, 11, 16, and 18.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:54:15.027Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of cervical cancer caused by HPV types 16 and 18"},{"name":"Prevention of genital warts caused by HPV types 6 and 11"},{"name":"Prevention of anal cancer and other HPV-related malignancies"}]},"trialDetails":[{"nctId":"NCT07407569","phase":"PHASE2","title":"Developing a First-void Urine-based Infection Model to Study HPV-specific Antibody-virion Interaction Before and After HPV Vaccination","status":"RECRUITING","sponsor":"Universiteit Antwerpen","startDate":"2026-03-25","conditions":"Human Papilloma Virus Infection Type 16","enrollment":50},{"nctId":"NCT06688058","phase":"PHASE1","title":"A Trial to Evaluate Tolerability and Immunogenicity of V540D in Healthy Adults (V540D-004)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-12-20","conditions":"Healthy","enrollment":72},{"nctId":"NCT03943875","phase":"PHASE4","title":"GARDASIL 9: 3 Dose vs. 2 Dose With Delayed 3rd Dose","status":"ACTIVE_NOT_RECRUITING","sponsor":"The University of Texas Medical Branch, Galveston","startDate":"2019-06-17","conditions":"Immunization, Efficacy, Human Papilloma Virus","enrollment":767},{"nctId":"NCT03284866","phase":"PHASE3","title":"HPV Vaccine Therapy in Reducing High-Grade Cervical Lesions in Patients With HIV and HPV","status":"COMPLETED","sponsor":"AIDS Malignancy Consortium","startDate":"2019-07-31","conditions":"AIDS-Related Human Papillomavirus Infection, High Grade Cervical Squamous Intraepithelial Neoplasia, HIV Infection","enrollment":536},{"nctId":"NCT06752083","phase":"","title":"Efficacy of Lentinula Edodes-Derived Supplement (AHCC®) in Promoting Negativity of Persistent HPV Infection","status":"COMPLETED","sponsor":"Liaquat University of Medical & Health Sciences","startDate":"2023-01-02","conditions":"HPV Infection","enrollment":289},{"nctId":"NCT06786429","phase":"PHASE4","title":"Managing Hepatitis B (Hep. B) and Human Papilloma Virus (HPV) Related Cancers and Mental Health.","status":"NOT_YET_RECRUITING","sponsor":"Eunice Dube","startDate":"2026-08-30","conditions":"Hepatitis B, Human Papilloma Virus, Gall Stones (& [Calculus - Gall Bladder])","enrollment":1800},{"nctId":"NCT06436274","phase":"PHASE4","title":"Efficacy of Human Papillomavirus (HPV) Vaccination to Prevent Infection Among Women Living With HIV.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2024-10-14","conditions":"Human Papilloma Virus, Hiv","enrollment":778},{"nctId":"NCT07314307","phase":"PHASE4","title":"Vaccine Effectiveness of One Dose of the Nonavalent Human Papillomavirus (HPV) Vaccine Among Young-adult Women in Sweden Among Women Participating in a Clinical Trial of Concomitant HPV Vaccination and Screening","status":"ACTIVE_NOT_RECRUITING","sponsor":"Karolinska Institutet","startDate":"2021-05-03","conditions":"Incident HPV16, 18, 31, 33, 45, 52 or 58 Infection","enrollment":150000},{"nctId":"NCT03023631","phase":"PHASE4","title":"Gardasil 9 Vaccine in Preventing HPV Infection in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-04-23","conditions":"Allogeneic Hematopoietic Stem Cell Transplant Recipient, Hematopoietic and Lymphoid Cell Neoplasm","enrollment":48},{"nctId":"NCT05031078","phase":"PHASE4","title":"Assessing Durable Antibody Response to HPV Vaccination","status":"ACTIVE_NOT_RECRUITING","sponsor":"Emory University","startDate":"2021-12-21","conditions":"HPV","enrollment":17},{"nctId":"NCT04265950","phase":"PHASE4","title":"Establishing Optimal Number of Doses for HPV Vaccination in Children and Adolescents Living With HIV, OPTIMO Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2022-03-10","conditions":"HIV Infection","enrollment":97},{"nctId":"NCT03180034","phase":"PHASE4","title":"Comparing One or Two Doses of the Human Papillomavirus Vaccine for the Prevention of Human Papillomavirus Infection, ESCUDDO Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-11-29","conditions":"Human Papillomavirus Infection, Human Papillomavirus-Related Cervical Carcinoma","enrollment":27945},{"nctId":"NCT04982614","phase":"PHASE4","title":"HPV Vaccination in HIV Infected and HIV Uninfected Adolescents in Eswatini","status":"COMPLETED","sponsor":"Columbia University","startDate":"2022-04-01","conditions":"HPV Infection, Hiv, HPV Vaccine","enrollment":1403},{"nctId":"NCT06799494","phase":"PHASE4","title":"HPV Vaccine Reduced Dose","status":"RECRUITING","sponsor":"Emory University","startDate":"2025-08-06","conditions":"HPV","enrollment":100},{"nctId":"NCT06623409","phase":"PHASE1","title":"Safety and Immunogenicity of V540B in Healthy Adults (V540B-002).","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-11-12","conditions":"Healthy","enrollment":72},{"nctId":"NCT00092534","phase":"PHASE3","title":"Cervical Intraepithelial Neoplasm (CIN) in Women (Gardasil) (V501-015)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2002-06-14","conditions":"Cervical Cancer, Genital Warts","enrollment":12167},{"nctId":"NCT05557370","phase":"PHASE4","title":"Immunogenicity of HPV Vaccine in Transplant Recipients.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2023-06-01","conditions":"Chronic Kidney Diseases, Kidney Transplant","enrollment":30},{"nctId":"NCT00505063","phase":"PHASE2","title":"Prospective Trial of Vaccine Responses in Childhood Cancer Survivors","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2007-07-10","conditions":"Childhood Cancer, Multiple Diseases","enrollment":76},{"nctId":"NCT06588257","phase":"PHASE4","title":"Acceptability of the HPV Vaccine and Anal HPV in Transgender Women and Men Who Have Sex With Men: A Pilot Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fundación Huésped","startDate":"2024-10-09","conditions":"HPV","enrollment":101},{"nctId":"NCT06793410","phase":"PHASE2","title":"Vaccination Against Human Papillomavirus (HPV) After Allogeneic Stem Cell Transplantation","status":"RECRUITING","sponsor":"Vastra Gotaland Region","startDate":"2025-05-12","conditions":"Recipients of Allogeneic Stem Cell Transplantation, HPV (Human Papillomavirus)-Associated, Acute Myeloid Leukaemia","enrollment":100},{"nctId":"NCT01824537","phase":"PHASE4","title":"Transmission Reduction and Prevention With HPV Vaccination (TRAP-HPV) Study","status":"COMPLETED","sponsor":"McGill University","startDate":"2014-01","conditions":"Human Papillomavirus Infection","enrollment":372},{"nctId":"NCT06650956","phase":"NA","title":"Integration to Improve Adolescent Health and HPV Vaccination in Laos","status":"RECRUITING","sponsor":"Health Poverty Action","startDate":"2024-11-01","conditions":"Healthy, Adolescents, Integrated, Community-Health Systems","enrollment":700},{"nctId":"NCT05202860","phase":"PHASE2","title":"Impact of Human Papillomavirus (HPV) Vaccination on Burden of Disease in Patients with Actinic Keratosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merete Haedersdal","startDate":"2022-05-09","conditions":"Actinic Keratoses, Basal Cell Carcinoma, Squamous Cell Carcinoma","enrollment":70},{"nctId":"NCT02653118","phase":"","title":"Long-term Follow-up of Broad Spectrum Human Papillomavirus (HPV) Vaccine Study in Women (V503-021)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2016-01-22","conditions":"Cervical Cancer, Vulvar Cancer, Vaginal Cancer","enrollment":4453},{"nctId":"NCT06582654","phase":"","title":"Normalizing Antibody Detection in First-void Urine","status":"RECRUITING","sponsor":"Universiteit Antwerpen","startDate":"2023-12-07","conditions":"Human Papillomavirus Infection","enrollment":150},{"nctId":"NCT06536855","phase":"PHASE4","title":"Faster Elimination of HPV Infection and Cervical Cancer Using Concomitant HPV Vaccination and HPV Screening: A Demonstration Project in Rwanda","status":"NOT_YET_RECRUITING","sponsor":"Rwanda Biomedical Centre","startDate":"2024-09-01","conditions":"Cervical Cancer","enrollment":100000},{"nctId":"NCT06345885","phase":"PHASE4","title":"Immunogenicity and Safety of One Dose of HPV Vaccine","status":"COMPLETED","sponsor":"Xiamen Innovax Biotech Co., Ltd","startDate":"2023-02-23","conditions":"Human Papillomavirus Vaccines","enrollment":200},{"nctId":"NCT00667563","phase":"PHASE1","title":"Vaccine Therapy in Preventing HPV in HIV-Positive Women in India","status":"COMPLETED","sponsor":"AIDS Malignancy Consortium","startDate":"2009-08","conditions":"Cervical Cancer, Nonneoplastic Condition, Precancerous Condition","enrollment":150},{"nctId":"NCT06052696","phase":"PHASE4","title":"Adjuvant Nonavalent HPV Vaccination in Women Treated for Vulvar HSIL","status":"NOT_YET_RECRUITING","sponsor":"Erasmus Medical Center","startDate":"2023-12-01","conditions":"Vulvar HSIL, HPV","enrollment":500},{"nctId":"NCT01914367","phase":"PHASE4","title":"Study of the Molecular Mechanisms Underlying the Cross-neutralizing Capacity of AS04-adjuvanted HPV Vaccine (Cervarix®) in Comparison With the Aluminiumhydroxyphosphate Sulphate Adjuvanted HPV Vaccine (Gardasil®)","status":"COMPLETED","sponsor":"University Hospital, Ghent","startDate":"2013-06-25","conditions":"Infection With Human Papillomavirus","enrollment":12},{"nctId":"NCT03947775","phase":"PHASE2","title":"HPV-SAVE_Merck_Sub-Study for Preventing Recurrence of HSIL","status":"NOT_YET_RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2022-09-01","conditions":"Anal Intraepithelial Neoplasia, Anal Cancer, Human Papilloma Virus","enrollment":228},{"nctId":"NCT05149248","phase":"PHASE2, PHASE3","title":"Prevention and Control of Neoplasms Associated With HPV in High-risk Groups in Mexico City: The Condesa Study","status":"COMPLETED","sponsor":"Instituto Nacional de Salud Publica, Mexico","startDate":"2018-05-30","conditions":"Cancer of Cervix","enrollment":6000},{"nctId":"NCT01924754","phase":"","title":"Gardasil Immunogenicity With Needle-Free Injection","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2014-01-01","conditions":"HPV Seroconversion","enrollment":150},{"nctId":"NCT04391647","phase":"","title":"Developing Methods to Investigate Additional Opportunities of HPV Vaccination by Using First-void Urine Samples","status":"COMPLETED","sponsor":"Universiteit Antwerpen","startDate":"2020-05-11","conditions":"Human Papilloma Virus Infection","enrollment":50},{"nctId":"NCT01209325","phase":"PHASE2","title":"Vaccine Therapy in Preventing Human Papillomavirus Infection in Young HIV-Positive Male Patients Who Have Sex With Males","status":"COMPLETED","sponsor":"AIDS Malignancy Consortium","startDate":"2011-06-28","conditions":"Anal Cancer, Nonneoplastic Condition, Penile Cancer","enrollment":149},{"nctId":"NCT03105856","phase":"PHASE4","title":"FASTER-Tlalpan Study in Mexico: HPV Vaccination Impact on Cervical Cancer Screening Program","status":"COMPLETED","sponsor":"Instituto Nacional de Salud Publica, Mexico","startDate":"2017-01-03","conditions":"Cervical Intraepithelial Neoplasia, HPV-Related Cervical Carcinoma","enrollment":3000},{"nctId":"NCT01092195","phase":"PHASE1","title":"Gardasil Vaccination in Post Stem Cell Transplant Patients","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2010-06-02","conditions":"Gardasil Vaccine, Stem Cell Transplant, Immunogenicity","enrollment":64},{"nctId":"NCT01375868","phase":"PHASE3","title":"Effect of Vaccination in Patients With Recurrent Respiratory Papillomatosis","status":"COMPLETED","sponsor":"Ruth Tachezy, PhD.","startDate":"2011-10","conditions":"Squamous Papilloma of the Larynx","enrollment":51},{"nctId":"NCT00543543","phase":"PHASE3","title":"Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-09-24","conditions":"Cervical Cancer, Vulvar Cancer, Vaginal Cancer","enrollment":14840},{"nctId":"NCT01717118","phase":"PHASE4","title":"Evaluation of Immunogenicity Levels in Women With HPV Vaccine in Mexico","status":"COMPLETED","sponsor":"Instituto Nacional de Salud Publica, Mexico","startDate":"2009-11","conditions":"Healthy","enrollment":2000},{"nctId":"NCT01343485","phase":"NA","title":"Innovative Tool to Increase Completion of Human Papillomavirus (HPV) Vaccine Series","status":"COMPLETED","sponsor":"Planned Parenthood Federation of America","startDate":"2011-09","conditions":"GARDASIL Vaccination","enrollment":365},{"nctId":"NCT02196454","phase":"NA","title":"Video to Promote HPV Vaccination","status":"COMPLETED","sponsor":"Children's Hospital of Philadelphia","startDate":"2014-07","conditions":"Vaccine Acceptance, Social Acceptance, Acceptance Processes","enrollment":110},{"nctId":"NCT03296397","phase":"PHASE3","title":"Efficacy of Quadrivalent HPV Vaccine to Prevent Relapses of Genital Warts After Initial Therapeutic Response","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2017-11-15","conditions":"Genital Warts","enrollment":300},{"nctId":"NCT00806676","phase":"NA","title":"Antibody Response to Human Papillomavirus Recombinant Vaccine (Gardasil®) in Girls and Young Women With Chronic Kidney Disease","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2008-12","conditions":"Chronic Kidney Disease","enrollment":67},{"nctId":"NCT01078220","phase":"","title":"Observational Surveillance Study to Detect Potential Safety Signals in Patients Who Have Had at Least One Dose of GARDASIL™ (V501-031)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-02-06","conditions":"Human Papillomavirus Infection","enrollment":189629},{"nctId":"NCT02714114","phase":"","title":"Standard Operating Procedures for Anti-HPV (Human Papillomavirus) Antibody Detection in First-void Urine (AB-SOP Study)","status":"COMPLETED","sponsor":"Universiteit Antwerpen","startDate":"2015-09","conditions":"Human Papilloma Virus Infection","enrollment":57},{"nctId":"NCT01062074","phase":"","title":"GARDASIL Reexamination Study (V501-059)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-09-28","conditions":"Human Papillomavirus (HPV) Infection","enrollment":3605},{"nctId":"NCT00941889","phase":"NA","title":"The Effect of HPV Vaccination on Recurrence Rates in HIV Patients With Condylomata","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2007-07","conditions":"HIV Positive, Anal Condylomata, Anal Warts","enrollment":32},{"nctId":"NCT02464358","phase":"NA","title":"An Information-Motivation-Behavioral Skills (IMB) Intervention to Promote Human Papillomavirus Vaccination Among Women","status":"COMPLETED","sponsor":"University of Connecticut","startDate":"2011-12","conditions":"Human Papillomavirus Infection","enrollment":70},{"nctId":"NCT00680147","phase":"PHASE2","title":"Human Papillomavirus (HPV) Vaccination Acceptance by African-American Parents: Identifying Psychosocial Barriers","status":"COMPLETED","sponsor":"Syracuse University","startDate":"2008-07","conditions":"HPV","enrollment":614},{"nctId":"NCT00813319","phase":"PHASE3","title":"Girls OnGuard: HPV Vaccination Uptake Among African American Adolescent Females","status":"COMPLETED","sponsor":"Emory University","startDate":"2009-10","conditions":"Vaccination","enrollment":216},{"nctId":"NCT01393470","phase":"","title":"Evaluation of Long-term HPV Vaccine Efficacy","status":"UNKNOWN","sponsor":"Tampere University","startDate":"2011-05","conditions":"Uterine Cervical Cancer","enrollment":10000},{"nctId":"NCT01424644","phase":"PHASE4","title":"A Phase 4, Placebo-Controlled, Randomized Study to Evaluate the Immunogenicity and Safety of HPV and Tdap When Administered With MenACWY in Adolescents","status":"COMPLETED","sponsor":"Novartis","startDate":"2011-09","conditions":"Meningococcal Meningitis","enrollment":801},{"nctId":"NCT01995721","phase":"PHASE3","title":"4-valent HPV Vaccine to Treat Recurrent Respiratory Papillomatosis in Children","status":"UNKNOWN","sponsor":"National Institute of Child Health, Hungary","startDate":"2014-02","conditions":"Recurrent Respiratory Papillomatosis","enrollment":20},{"nctId":"NCT00911521","phase":"PHASE4","title":"Immunogenicity and Safety of a Quadrivalent Human Papillomavirus (HPV) Vaccine in Patients With SLE: a Controlled Study","status":"COMPLETED","sponsor":"Tuen Mun Hospital","startDate":"2009-10","conditions":"Systemic Lupus Erythematosus","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":714,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Vaccination with Gardasil","genericName":"Vaccination with Gardasil","companyName":"Assistance Publique - Hôpitaux de Paris","companyId":"assistance-publique-h-pitaux-de-paris","modality":"Biologic","firstApprovalDate":"","aiSummary":"Gardasil is a recombinant quadrivalent human papillomavirus (HPV) vaccine that stimulates the immune system to produce antibodies against HPV types 6, 11, 16, and 18. Used for Prevention of cervical cancer caused by HPV types 16 and 18, Prevention of genital warts caused by HPV types 6 and 11, Prevention of anal cancer and other HPV-related malignancies.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}